Entrectinib
- Generic Name
- Entrectinib
- Brand Names
- Rozlytrek
- Drug Type
- Small Molecule
- Chemical Formula
- C31H34F2N6O2
- CAS Number
- 1108743-60-7
- Unique Ingredient Identifier
- L5ORF0AN1I
- Background
Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors. Entrectinib's approved ...
- Indication
Entrectinib is indicated for the treatment of metastatic ROS1-positive non-small cell lung cancer in adults. Entrectinib is also indicated in adults and children over 12 years old for the treatment of NTRK gene fusion-positive solid tumors which have metastasized or for which surgical resection is likely to result in severe morbidity and for which has progre...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Metastatic Solid Neoplasm, Solid Tumors
- Associated Therapies
- -
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
- First Posted Date
- 2015-10-05
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 534
- Registration Number
- NCT02568267
- Locations
- 🇺🇸
University of Southern California Medical Center, Los Angeles, California, United States
🇺🇸Cancer Treatment Centers of America - Eastern Regional Medical Center, Philadelphia, Pennsylvania, United States
🇺🇸Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.
- Conditions
- Interventions
- First Posted Date
- 2014-03-27
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 84
- Registration Number
- NCT02097810
- Locations
- 🇺🇸
Florida Cancer Specialists - Sarasota, Sarasota, Florida, United States
🇺🇸University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.